Redcare Pharmacy lifts FY 2026 revenue growth outlook to 16%-18%

Bitget2026/09/28 11:49

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Redcare Pharmacy lifted full-year 2026 revenue guidance for a second time, citing sustained prescription-drug momentum in Germany.
Total revenue growth now seen at 16% to 18%, up from 15% to 17%; non-Rx growth maintained at 10% to 12%.
Germany Rx revenue forecast raised to EUR 730-760 million, implying 45% to 51% growth versus EUR 680-720 million previously.
Adjusted EBITDA margin outlook kept at 2.5% to 3.0%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redcare Pharmacy NV published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2406332_en) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Yardeni Research has lowered its year-end S&P 500 target to 7,900 points and reduced its valuation target to 18.6 times, mainly due to risk-off sentiment suppressing valuations rather than deteriorating earnings. Despite facing risk aversion and policy risks, Yardeni remains optimistic about corporate earnings and the medium-to-long-term economy, viewing pullbacks as buying opportunities.

华尔街见闻•2026/10/15 13:26